诺和诺德：Ozempic获得欧盟附带条件的推荐。

Core Insights - Novo Nordisk's Ozempic has received a conditional recommendation from the European Union [1] Company Summary - The recommendation is part of the EU's regulatory process, indicating potential approval for Ozempic under specific conditions [1] - This development may enhance Novo Nordisk's market position in the diabetes treatment sector [1] Industry Summary - The conditional recommendation reflects ongoing advancements in diabetes medications within the pharmaceutical industry [1] - The EU's decision could influence market dynamics and competition among diabetes drug manufacturers [1]